ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Imeglimin halts cyclophosphamide-induced ovarian injury: a dual modulation of TLR4/NF-κB/NLRP3-driven inflammation and AMPK/SIRT1/PGC-1α pathways.

Reham H Mohyeldin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.